Priser
Platform
Blog
Om os
Download
300204
Staidson Beijing Biopharmaceuticals Co
Shenzhen Stock Exchange
0

Om

Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a prominent biopharmaceutical company that focuses on the research, development, and production of innovative therapeutic drugs. Its primary function is to address various health needs by developing advanced biopharmaceutical solutions. The company specializes in creating solutions for treating infectious diseases, autoimmune disorders, and other critical medical conditions. It plays a significant role in the healthcare industry by investing in cutting-edge research and employing biotechnological advancements to enhance treatment efficacy and patient well-being. As a vital player in the biopharmaceutical sector, Staidson's contributions help advance medical care and therapeutic options, impacting healthcare outcomes on a global scale. Through its commitment to innovation and quality, Staidson aims to meet the demands of a rapidly evolving healthcare environment.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I STAIDSON BEIJING BIOPHARMACEUTICALS CO MED ENDAVU: Køb Staidson Beijing Biopharmaceuticals Co ($300204) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Staidson Beijing Biopharmaceuticals Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker300204
Land
Kina
Antal medarbejdere492
Hjemmesidestaidson.com
SektorSundhed
IndustriBioteknologi

Udbytter

0,03CNH
'14
0,08CNH
'15
0,15CNH
'16
0,18CNH
'17
0,25CNH
'18
0,67CNH
'19
Ex-udbytte-dato17. maj 2019
Udbytteafkast2,42%